1 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy [HOPE-2] Updated Results from the Interim Analysis Presented at the 24th International Annual Congress of the World Muscle Society October 7, 2019 Conference Call NASDAQ: CAPR Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical tria ...